Literature DB >> 28070752

Absence of macrophage migration inhibitory factor reduces proliferative retinopathy in a mouse model.

Jing Wang1, Jihong Lin1, Ulrike Kaiser1, Paulus Wohlfart2, Hans-Peter Hammes3.   

Abstract

AIMS: Ischemia-induced neovascularization is the key feature of proliferative diabetic retinopathy. Macrophage migration inhibitory factor (MIF) is a pleiotropic proinflammatory and proangiogenic cytokine, and its levels are elevated in the vitreous of patients with proliferative diabetic retinopathy. In this study, we aimed at investigating the relative potential of MIF in the ischemia-induced retinal neovascularization.
METHODS: Both WT and MIF-knockout mice were subjected to the retinopathy of prematurity (ROP) model. Intraretinal vessel regrowth was assessed by whole-mount immunofluorescence, and preretinal neovascularization was analyzed in retinal vertical sections after periodic acid-Schiff staining in the hypoxic stage of the ROP model. Gene expression of selected proangiogenic and proinflammatory factors at postnatal day 13 (p13) was measured by real-time PCR. Vascular endothelial growth factor (VEGF) expression, recruitment of endothelial progenitor cells (EPCs) and microglial activation were analyzed with immunofluorescence.
RESULTS: MIF deficiency increased areas of vascular obliteration by 49%, reduced sprouting tips by 27% and inhibited preretinal angiogenesis by 35%. VEGF expression was reduced in Müller cells of MIF-knockout mice. MIF absence reduced gene expression of erythropoietin, tumor necrosis factor alpha and intercellular adhesion molecule-1 by 30, 70 and 50%, respectively, decreased the number of retinal EPCs by 37.5% and inhibited microglial activation in the hypoxic condition.
CONCLUSIONS: In conclusion, we found that MIF has proangiogenic and proinflammatory properties in retinal neovascularization. The proangiogenic role of MIF in ischemia-induced retinal neovascularization is associated with the expression of VEGF and erythropoietin, EPC recruitment and inflammation. Therefore, MIF has a potential role in the pathological angiogenesis of proliferative retinopathy.

Entities:  

Keywords:  Angiogenesis; Diabetic retinopathy; Inflammation; Macrophage migration inhibitory factor; Mice

Mesh:

Substances:

Year:  2017        PMID: 28070752     DOI: 10.1007/s00592-016-0956-8

Source DB:  PubMed          Journal:  Acta Diabetol        ISSN: 0940-5429            Impact factor:   4.280


  7 in total

1.  Role of the Endothelium in Neonatal Diseases.

Authors:  Olachi J Mezu-Ndubuisi; Akhil Maheshwari
Journal:  Newborn (Clarksville)       Date:  2022-03-31

Review 2.  A Pathogenic Relationship of Bronchopulmonary Dysplasia and Retinopathy of Prematurity? A Review of Angiogenic Mediators in Both Diseases.

Authors:  Ashley Stark; Christiane Dammann; Heber C Nielsen; MaryAnn V Volpe
Journal:  Front Pediatr       Date:  2018-06-13       Impact factor: 3.418

3.  Comprehensive analysis of vitreous chemokines involved in ischemic retinal vein occlusion.

Authors:  Yunkao Zeng; Dan Cao; Honghua Yu; Xuenan Zhuang; Dawei Yang; Yunyan Hu; Miao He; Liang Zhang
Journal:  Mol Vis       Date:  2019-11-15       Impact factor: 2.367

4.  Mapping research trends in diabetic retinopathy from 2010 to 2019: A bibliometric analysis.

Authors:  Yi Dong; Yanli Liu; Jianguo Yu; Shixin Qi; Huijuan Liu
Journal:  Medicine (Baltimore)       Date:  2021-01-22       Impact factor: 1.889

Review 5.  Role of macrophages in fetal development and perinatal disorders.

Authors:  Olachi J Mezu-Ndubuisi; Akhil Maheshwari
Journal:  Pediatr Res       Date:  2020-10-18       Impact factor: 3.756

6.  Whole-genome sequencing suggests a role of MIF in the pathophysiology of TEMPI syndrome.

Authors:  Chunyan Sun; Jian Xu; Bo Zhang; Haifan Huang; Lei Chen; Han Yan; Aoshuang Xu; Fei Zhao; Daijuan Huang; Liqiong Liu; Jian Li; Yu Hu
Journal:  Blood Adv       Date:  2021-06-22

7.  The Proinflammatory and Proangiogenic Macrophage Migration Inhibitory Factor Is a Potential Regulator in Proliferative Diabetic Retinopathy.

Authors:  Ahmed M Abu El-Asrar; Ajmal Ahmad; Mohammad Mairaj Siddiquei; Alexandra De Zutter; Eef Allegaert; Priscilla W Gikandi; Gert De Hertogh; Jo Van Damme; Ghislain Opdenakker; Sofie Struyf
Journal:  Front Immunol       Date:  2019-12-04       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.